Puration, Inc. (OTCMKTS:PURA) Partnerships Create Strong Web of Support

Puration, Inc. (OTCMKTS:PURA) is just a few weeks removed from its launch of EVERx CBD-Infused Bottled Water, and EVERx Alkaline Bottled Water at the Arnold (Schwarzenegger) Sports Festival in Columbus, Ohio. The product line was borne from a partnership between PURA and Alkame Holdings, Inc. (OTCMKTS:ALKM).

In fact, many of our readers might not know that PURA is actually a spin-off of North American Cannabis Holdings, Inc. (OTCMKTS:USMJ), with whom the company still works. The two companies published a joint online, on-demand presentation about PURA producing EVERx CBD Infused Water under a license from USMJ.

USMJ is preparing for the upcoming launch of AmeriCanna Cafe, which will be officially rolled out at the Southwest Cannabis Conference & Expo to be held in Fort Worth, Texas on April 22nd and 23rd, at which the joint presentation with Puration, Inc. (OTCMKTS:PURA) will be shown.

But that’s not the only key partnership that could soon be yielding big-time results for PURA. This week the company announced that NCM Biotech has licensed to PURA, the right to utilize NCM Biotech’s patented cannabis extraction process to produce cannabis extracts for infusion into recreational, fitness wellness, alternative medicine and beauty products. NCM Biotech exclusively owns U.S. Patent No. 9,199,960, entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”.The license of the process to PURA is the first and only license NCM Biotech has executed.

NCM Biotech’s medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Research and development with NCM Biotech’s patented process has demonstrated a high potential for bringing FDA approved pharmaceutical products to market, for the treatment of multiple neurological disorders and cancer. The license agreement with PURA is specifically designed to accelerate funding for the FDA approval process, through proceeds generated by PURA’s sales of extracts for infusion into non-pharmaceutical consumer products. Beech Tree Labs is slated to manage the FDA approval process.

According to NCM Founder and CEO Frederick Ferri, “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development, have a greater efficacy potential than GW Pharmaceutical products and candidate products. We are very enthusiastic about working with Puration, to rapidly ramp-up non-pharmaceutical extract sales offering the highest quality extracts available in the growing cannabis market, and in turn using those sales to fund our ongoing pharmaceutical product development and FDA approval process.”

In the same release we learned that PURA plans to introduce three new EVERx CBD Infused sports nutritional supplement products later this month, in conjunction with the upcoming annual 4/20 celebration. (Source: PR Newswire)

Brian Shibley, CEO of Puration also iterated the company’s plans to secure financing to build a commercial extraction lab that can support the magnitude of sales interest already generated, with just the introduction of one product. We were told to look out for new product rollouts later this month as well, so we’ll definitely have our ears to the tracks looking for that.

The biggest downside we can see with PURA is that the company has so many irons in the fire that it can be difficult to keep track of them all. However that could also be viewed as a positive, with the company’s product development happening at breakneck speeds. It’s a story we will want to continually track moving forward. Get yourself signed up for Street Register’s 100% free newsletter below to stay up to date on PURA.

Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Mar 2024 to Apr 2024